Common Protein Found in Dementia and ALS

Join Our Community of Science Lovers!

Globs of malformed protein are conspicuously present in many degenerative disorders of the brain and nervous system. A number of these possibly damaging proteins have been isolated and studied, but researchers have struggled to characterize certain protein deposits in the brains of people with frontotemporal dementia (FTD), the second most common type of dementia after Alzheimer's disease. Scientists have now revealed the offending molecule and discovered that it also shows up in those with Lou Gehrig's disease, a debilitating neuromuscular disorder, suggesting that the two conditions might have intersecting routes on the pathway to cell death.

In people with FTD, the frontal and temporal lobes of the brain shrink and their behavior changes. They may become fixated on sex or engage in criminal behavior, and they eventually die from the disorder. Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS), would seem like a different beast, given that it causes degeneration in motor neurons. But in recent years neurologists have observed that people with one of the conditions tend to get the other.

Researchers have long known that in about half of FTD cases, brains are speckled with protein clumps containing tau, a protein implicated in Alzheimer's and other brain diseases. In the other fraction of FTD cases, the deposited protein was unknown. To identify the mystery molecule, neurobiologists Virginia Lee and John Trojanowski of the University of Pennsylvania and their colleagues isolated a group of proteins from brain samples of people with FTD. They injected the molecules into mice to create antibodies capable of recognizing the various suspect proteins, and then searched through the antibodies to find those that stuck only to the clumps in brain samples of FTD patients. The search turned up an obscure protein, TDP-43, they report in the October 6 Science. The antibodies also clung to protein deposits in motor neuron samples from ALS patients, indicating that TDP-43 was present there, too.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


"What that strongly suggests," says neurobiologist Michael Hutton of the Mayo Clinic in Jacksonville, Fla., who was not involved in the research, "is that in each of these diseases there is at some point a common pathway to neuronal cell death. We've long suspected this might be the case; we just didn't realize it was the same major protein accumulating." From here, he explains, researchers can begin studying how TDP-43 deposits arise in, and maybe contribute to, the diseases.

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe